ClinicalTrials.gg
CompletedNCT02442765Updated Feb 13, 2023Results posted

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

A Phase 3 interventional study of AVP-786 and Placebo in Agitation in Patients With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 126 sites in 6 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-02-13.

Primary conditionDementiaRegistry: Psychomotor AgitationReclassifiedWhy we changed it
Registry
Psychomotor Agitation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dementia
Why
  1. The registry often attaches Psychomotor Agitation to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
387
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Dementia by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Dementia · Otsuka Holdings Co., Ltd..

Enrollment
5th of 10
387 · median 377
Started
2015
with 2 others
Phase 3
8 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 7th registered.

Dementia

2,376 studies on the registry are indexed under Dementia; 573 are open to participants now.

Browse Dementia studies →

Open to participants now

None of the 11 studies in Dementia by Otsuka Holdings Co., Ltd. is open now. The open studies under Dementia, anywhere →

Who these studies take

Of the 382 Dementia studies recruiting now, 243 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 163 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Dementia by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.

Read the detailed description

Eligible participants for this study must have had a diagnosis of probable AD and must have had clinically meaningful agitation secondary to AD.

This was to be a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment.

Approximately 380 participants were to be enrolled at approximately 60 centers in North America.

Study medication was to be administered orally twice-daily from Day 1 through Day 85. Screening was to occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants were to be randomized into the study.

03

Conditions studied

  • Agitation in Patients With Dementia of the Alzheimer's Type

Browse trials for

Keywords

  • Agitation
  • Dementia
  • Alzheimer's disease
04

In context

Dementia Reclassified

2,376 studies on the registry are indexed under Dementia; 573 are open to participants now.

This study's enrollment of 387 is above the median of 90 across 1,762 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Compared within Dementia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psychomotor Agitation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria
  • The participant has , moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization
  • The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation
  • Either out patients or residents of an assisted-living facility or a skilled nursing home
  • Clinical Global Impression of Severity of Illness (CGIS) score assessing Agitation is >= 4 (moderately ill) at screening and baseline
  • (MMSE) score is between 6 and 26 (inclusive) at screening and baseline
  • Caregiver who is able and willing to comply with all required study procedures. In order to qualify as a reliable informant (i.e., caregiver) capable of assessing changes in participant's condition during the study, the individual must spend a minimum of 2 hours per day for 4 days per week with the participant.

Exclusion criteria

Exclusion Criteria:

  • Participant has dementia predominantly of non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)
  • Participants with co-existent or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., , poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)
  • Participant with myasthenia gravis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
387 participants (actual)

Study arms

  • Placebo comparator
    Stage 1: Placebo

    Participants received matching placebo orally twice daily (BID) for 6 weeks (Days 1-42) in Stage 1. Participants who completed Stage 1 were eligible to Participate in Stage 2.

    Drug: Placebo

  • Experimental
    Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)

    Participants received AVP-786-18 mg orally once daily (QD) in the morning and placebo orally QD in the evening for the first 7 days, followed by AVP-786-18 mg orally BID for the remaining 5 weeks (Days 8-42). Participants who completed Stage 1 were eligible to participate in Stage 2.

    Drug: AVP-786

  • Experimental
    Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)

    Participants received AVP-786-18 mg orally QD in the morning and placebo orally QD in the evening for the first 7 days, followed by AVP-786-18 mg orally BID for 2 weeks (Days 8-21). From Day 22, participants received AVP-786-28 mg orally BID for the remaining 3 weeks. Participants who completed Stage 1 were eligible to participate in Stage 2.

    Drug: AVP-786

  • Placebo comparator
    Stage 2: Placebo

    Participants who received matching placebo orally BID for 6 consecutive weeks in Stage 1 were re-randomized in Stage 2 to receive the study drug or placebo from Day 43 to Day 85.

    Drug: Placebo

  • Experimental
    Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)

    Participants who received AVP-786-18 mg in Stage 1 continued to receive AVP-786-18 mg orally BID for the 6 weeks (Days 43-85) in Stage 2..

    Drug: AVP-786 · Drug: Placebo

  • Experimental
    Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)

    Participants who received AVP-786-28 mg in Stage 1 continued to receive AVP-786-28 mg orally BID for 6 weeks (Days 43-85) in Stage 2

    Drug: AVP-786 · Drug: Placebo

  • Experimental
    Experimental: Stage 1: Placebo to: Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mg

    Participants who were placebo responders or non-responders in Stage 1 received AVP-786-18 for 1 week, orally, QD, followed by AVP-786-18 BID for 2 weeks; followed by AVP-786-28 BID for the last 3 weeks.

    Drug: AVP-786 · Drug: Placebo

  • Experimental
    Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg

    Participants who were placebo responders or non-responders in Stage 1 received AVP-786-28 for 1 week, orally, QD, followed by AVP-786-28 BID for 2 weeks; followed by AVP-786-28 BID for the last 3 weeks.

    Drug: AVP-786 · Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12

    The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency: 1, never; 2, less than once a week; 3, once or twice a week; 4, several times a week; 5, once or twice a day; 6, several times a day; 7, several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

Secondary outcomes

  1. Least Squares Mean Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score at Week 6 and Week 12

    The intent of the ADCS version of the CGIC is to provide a means to reliably assess the global impression of change from Baseline in a clinical trial. The mADCS-CGIC is a modification of the ADCS-CGIC instrument that focuses specifically on agitation. The participants are asked to rate their impression of change from Baseline as: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Baseline was defined as the last non-missing assessment prior to Stage 1 randomization. Treatment effects were estimated at each stage by analysis of covariance (ANCOVA) with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \[vs\] \> 6), risk assessments for falls (normal/mild vs moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by last observation carried forward (LOCF) within each stage.

    Time frame: Stage 1 Week 6; Stage 2 Week 12

  2. Stage 1 and Stage 2: Change From Baseline in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score to Week 6 and Week 12

    The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate psychopathology, neuropsychiatric manifestations, and caregiver distress. The Agitation/Aggression domain is designed to collect information on the behavioral aspects of agitation/aggression in participants with probable Alzheimer's Disease (AD) and clinically meaningful agitation secondary to AD. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  3. Stage 1 and Stage 2: Change From Baseline in the NPI Caregiver Distress Score to Week 6 and Week 12

    The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate caregiver distress. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, marked severe. The total caregiver distress score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  4. Stage 1 and Stage 2: Change From Baseline in the NPI Aberrant Motor Behavior Domain Score to Week 6 and Week 12

    The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate aberrant motor behavior. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  5. Stage 1 and Stage 2: Change From Baseline in the Zarit Burden Interview (ZBI) Score to Week 6 and Week 12

    The ZBI is a 22-item scale used to assess the impact of a participant with dementia and also other illnesses on the caregiver's burden. For each item of the scale, the caregiver indicates how often they feel the burden (never, rarely, sometimes, quite frequently, or nearly always). The score ranges from 0 to 88 and is determined by adding the numbered responses of the individual items. Higher scores indicate greater caregiver distress. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  6. Stage 1 and Stage 2: Change From Baseline in the NPI Irritability/Lability Domain Score to Week 6 and Week 12

    The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains, including the irritability/lability domain score. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  7. Stage 1 and Stage 2: Change From Baseline in the NPI Total Score to Week 6 and Week 12

    NPI evaluates both frequency and severity of 12 neuropsychiatric disturbances including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, as well as appetite/eating. Total domain score= frequency x severity and thus ranges from 1 to 12. NPI domain is rated by caregiver for symptom frequency and severity. Frequency is rated as: 1=occasionally, 2=often, 3= frequently, and 4=very frequently. Severity is rated as: 1=mild; 2= moderate, and 3=severe. Frequency and severity rating scales has defined anchor points to enhance reliability of caregiver responses. Caregiver distress is rated for each positive neuropsychiatric symptom using following anchored scores. It is rated as 0=not at all, 1=minimal, 3=moderate, 4=severe, 5=very severe. Total score is calculated by adding the individual Item scores, to yield a possible total scores of 0 to 144.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  8. Stage 1 and Stage 2: Change From Baseline in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score to Week 6 and Week 12

    The CGIS-Agitation is an observer-rated scale that measures illness severity. CGIS is used to assess the severity of agitation. The CGIS score is rated on a 7-point scale (1 = normal, not at all ill; 7 = among the most extremely ill participants). Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  9. Stage 1 and Stage 2: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Rating at Week 6 and Week 12

    The ADCS-CGIC rating scale provides a reliable means to assess change from a Baseline level of global function within the time frame of the trial. ADCS-CGIC-Overall focuses on the clinician's observations of change in the participant's cognitive, functional, and behavioral performance. The ADCS-CGIC-Overall responses (1-7) are rated as: 1 = marked improvement, 2 = moderate improvement, 3 = minimal improvement, 4 = no change, 5 = minimal worsening, 6 = moderate worsening, or 7 = marked worsening. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  10. Stage 1 and Stage 2: Patient Global Impression of Change (PGIC) Score at Week 6 and Week 12

    The PGIC is a 7-point (1-7) scale used to assess treatment response: 1 = very much improved, = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  11. Stage 1 and Stage 2: Change From Baseline in the Dementia Quality of Life (DEMQOL) Score to Week 6 and Week 12

    The DEMQOL scale is used to evaluate health-related QOL in participants with dementia and their caregivers. There are 2 versions of the DEMQOL: a 28-item version (rated by the participant); and a 31-item version (DEMQOL-proxy, rated by the caregiver). Both versions are recommended for evaluating participants (and their caregivers) with mild to moderate dementia. The DEMQOL total score ranges from 28 to 112. The DEMQOL-proxy is used for participants with severe dementia; the total score ranges from 31 to 124. For both versions, higher scores indicate greater QOL. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 vs \> 6), risk assessments for falls (normal/mild vs moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  12. Stage 1 and Stage 2: Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score to Week 6 and Week 12

    The CSDD scale is used to assess signs/symptoms of major depression in participants with dementia. CSDD has 19 items, and each item is rated for severity on the following scale of 0 to 2 (0 =absent, 1= mild/intermittent 2=severe). CSDD score is calculated by summing non-missing scores from each item score. The scale ranges from 0-no depression to 38 maximum depressions. Scores above 10 indicate a probable major depression, above 18 indicate a definite major depression, and below 6 as a rule are associated with the absence of significant depressive symptoms. Higher score indicated maximum depression.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  13. Stage 2: Percentage of Participants With General Medical Health Rating (GMHR) Score

    The GMHR is a global clinical rating for medical health, designed to quantify in a single number (1 to 4) the severity of general comorbidity in a participant with dementia. The ratings are: 1 = poor; 2 = fair; 3 = good; 4 = excellent to very good. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

    Time frame: Baseline; Week 12

  14. Stage 1 and Stage 2: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score to Week 6 and Week 12

    The ADAS is designed to evaluate the cognitive and non-cognitive behavioral dysfunction characteristics of participants with AD. The cognitive subscale (ADAS-cog) consists of 11 subsets related to memory, praxis, and language. ADAS-cog scores range from 0 to 70. Higher scores indicate greater cognitive impairment. The ADAS-cog is assessed for participants with an Mini-Mental State Examination (MMSE) score of ≥10 at the Baseline Visit. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.

    Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12

  15. Stage 1: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals

    RUD evaluates dementia participants utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. The RUD is administered as a semi-structured interview with the participant's primary caregiver and contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by caregiver) and the other focusing on the participant's use of healthcare resources. Information of caregivers who reported their responsibilities affected their work and who visited healthcare professionals from the interviews during Stage 1 is reported for this outcome measure. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

    Time frame: Stage 1: Week 6

  16. Stage 2: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals

    RUD evaluates dementia participants utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. The RUD is administered as a semi-structured interview with the participant's primary caregiver and contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by caregiver) and the other focusing on the participant's use of healthcare resources. Information of caregivers who reported their responsibilities affected their work and who visited healthcare professionals from the interviews during Stage 2 is reported for this outcome measure. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

    Time frame: Stage 2: Week 12

  17. Stage 1: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant

    RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on hours per day caregiver spent assisting participant from interviews during Stage 1 is reported for this outcome measure, where the following questions (Q), Q1= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as toilet visits, eating, dressing, grooming, walking, bathing? Q2= On typical care day during the last 30 days, how much time per day did you assist participant with tasks as (shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= On typical care day during last 30 days, how much time per day did you spend supervising (preventing dangerous events)?(Q3). Data is collected for treatment arm groups as pre-specified in protocol for this outcome measure.

    Time frame: Stage 1: Week 6

  18. Stage 2: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant

    RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on hours per day caregiver spent assisting participant from interviews during Stage 1 is reported for this outcome measure, where the following questions (Q), Q1= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as toilet visits, eating, dressing, grooming, walking, bathing? Q2= On typical care day during the last 30 days, how much time per day did you assist participant with tasks as (shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= On typical care day during last 30 days, how much time per day did you spend supervising (preventing dangerous events)?(Q3). Data is collected for treatment arm groups as pre-specified in protocol for this outcome measure.

    Time frame: Stage 2: Week 12

  19. Stage 1: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant

    RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on days caregiver spent assisting participant from interviews during Stage 1 is reported for outcome measure, where following questions (Q), Q1= During last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking, bathing) services to participant?; Q2= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= During last 30 days, how many days did you spend providing these services (supervising) to the participant?. Data is collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

    Time frame: Stage 1: Week 6

  20. 12-Week Parallel Group: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant

    RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on days caregiver spent assisting participant from interviews during Stage 1 is reported for outcome measure, where following questions (Q), Q1= During last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking, bathing) services to participant?; Q2= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= During last 30 days, how many days did you spend providing these services (supervising) to the participant?. Data is collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

    Time frame: 12-Week Parallel Group: Week 12

08

Results

Posted Feb 13, 2023

Participant flow

Total of 695 participants were screened of these, 308 participants failed screening, 387 participants were randomized out of which 382 participants had at least 1 post baseline efficacy assessment. (Modified Intent-to-Treat { mITT} population).

Stage 1- (Days 1 to 42)
Participant flow — Stage 1- (Days 1 to 42)
MilestoneStage 1: PlaceboStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)Stage 2: PlaceboStage 1: Placebo to: Stage 2: AVP-786-28 d6-DM 18 mg/Q 4.9 mgStage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mgStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Started194969700000
Completed194969700000
Not completed00000000
Stage 2- (Days 43 to 85)
Participant flow — Stage 2- (Days 43 to 85)
MilestoneStage 1: PlaceboStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)Stage 2: PlaceboStage 1: Placebo to: Stage 2: AVP-786-28 d6-DM 18 mg/Q 4.9 mgStage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mgStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Started0006396976566
Completed0005686925955
Not completed0007105611
Withdrew: Adverse event00026115
Withdrew: Death00011020
Withdrew: Lack of efficacy00010000
Withdrew: Protocol deviation00010000
Withdrew: Study participant withdrawal by parent or guardian00010104
Withdrew: Lost to follow-up00010310
Withdrew: Withdrawal by subject00002021
Withdrew: Reason not specified00001001

Outcome measures

PrimaryStage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12

The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency: 1, never; 2, less than once a week; 3, once or twice a week; 4, several times a week; 5, once or twice a day; 6, several times a day; 7, several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline73.9 ± 22.2372.3 ± 23.0871.7 ± 23.57———
Change from Baseline at Week 6-10.7 ± 15.29-13.9 ± 16.70-10.3 ± 13.54———
Stage 2 Baseline———66.0 ± 24.7168.9 ± 20.7965.3 ± 19.36
Change from Baseline at Week 12———-1.6 ± 11.08-5.6 ± 11.78-4.9 ± 12.13
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · mixed model repeated measures (MMRM) · p = =0.021 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -4.0 · 95% CI -7.4 to -0.6
  • Stage 1: Placebo vs Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · MMRM · p = =0.731 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -0.6 · 95% CI -3.9 to 2.7
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · MMRM · p = =0.157 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -3.5 · 95% CI -8.4 to 1.4
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · MMRM · p = =0.150 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -3.6 · 95% CI -8.4 to 1.3
  • Stage 1: Placebo vs Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · MMRM · p = =0.008 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Mmrm weighted z-statistic: -2.65Sequential Parallel Comparison Design (SPCD) was used with weight = 0.6 for Stage 1 and 0.4 for Stage 2.
  • Stage 1: Placebo vs Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · MMRM · p = =0.208 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Mmrm weighted z-statistic: -1.26SPCD was used with weight = 0.6 for Stage 1 and 0.4 for Stage 2.
SecondaryLeast Squares Mean Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score at Week 6 and Week 12

The intent of the ADCS version of the CGIC is to provide a means to reliably assess the global impression of change from Baseline in a clinical trial. The mADCS-CGIC is a modification of the ADCS-CGIC instrument that focuses specifically on agitation. The participants are asked to rate their impression of change from Baseline as: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Baseline was defined as the last non-missing assessment prior to Stage 1 randomization. Treatment effects were estimated at each stage by analysis of covariance (ANCOVA) with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \[vs\] \> 6), risk assessments for falls (normal/mild vs moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by last observation carried forward (LOCF) within each stage.

Time frame:
Stage 1 Week 6; Stage 2 Week 12
Reported as:
Least squares mean · score on a scale
Least Squares Mean Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score at Week 6 and Week 12
score on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Week 63.4 ± 1.133.2 ± 1.243.3 ± 1.12———
Stage 2 Week 12———3.9 ± 0.183.3 ± 0.183.5 ± 0.17
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · ANCOVA · p = 0.331 · Least squares mean difference: -0.1 · 95% CI -0.4 to 0.1
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · ANCOVA · p = 0.400 · Least squares mean difference: -0.1 · 95% CI -0.4 to 0.2
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = 0.014 · Least squares mean difference: -0.6 · 95% CI -1.1 to -0.1
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = 0.145 · Least squares mean difference: -0.4 · 95% CI -0.9 to 0.1
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = 0.012 · Spcd ols weighted z-statistic: -2.51OLS = ordinary least squares
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = 0.097 · Spcd ols weighted z-statistic: -1.66
SecondaryStage 1 and Stage 2: Change From Baseline in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score to Week 6 and Week 12

The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate psychopathology, neuropsychiatric manifestations, and caregiver distress. The Agitation/Aggression domain is designed to collect information on the behavioral aspects of agitation/aggression in participants with probable Alzheimer's Disease (AD) and clinically meaningful agitation secondary to AD. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline7.1 ± 2.396.5 ± 1.947.2 ± 2.42———
Change from Baseline at Week 6-1.8 ± 3.58-2.0 ± 3.03-2.1 ± 2.94———
Stage 2 Baseline———6.9 ± 2.846.3 ± 2.716.3 ± 2.81
Change from Baseline at Week 12———-1.7 ± 3.00-0.8 ± 3.15-0.9 ± 3.35
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · MMRM · p = =0.182 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -0.5 · 95% CI -1.3 to 0.2SPCD was used with weight = 0.6 for Stage 1 and 0.4 for Stage 2.
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · MMRM · p = =0.390 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -0.3 · 95% CI -1.1 to 0.4
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · MMRM · p = =0.462 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: 0.5 · 95% CI -0.8 to 1.7
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · MMRM · p = =0.528 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: 0.4 · 95% CI -0.8 to 1.6
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.695 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, Baseline (BL), BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Mmrm weighted z-statistic: -0.39
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.904 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, Baseline (BL), BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Mmrm weighted z-statistic: -0.12
SecondaryStage 1 and Stage 2: Change From Baseline in the NPI Caregiver Distress Score to Week 6 and Week 12

The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate caregiver distress. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, marked severe. The total caregiver distress score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the NPI Caregiver Distress Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline18.87 ± 9.02618.90 ± 9.26618.88 ± 10.015———
Change from Baseline at Week 6-4.31 ± 7.979-5.48 ± 8.559-4.83 ± 7.736———
Stage 2 Baseline———17.33 ± 9.01015.95 ± 7.24116.89 ± 7.416
Change from Baseline at Week 12———-0.73 ± 6.533-1.67 ± 5.6660.44 ± 7.265
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · MMRM · p = =0.247 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -1.2 · 95% CI -3.2 to 0.8
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · MMRM · p = =0.721 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -0.4 · 95% CI -2.3 to 1.6
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · MMRM · p = =0.419 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -1.2 · 95% CI -4.3 to 1.8
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · MMRM · p = =0.534 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: 0.9 · 95% CI -2.0 to 3.9
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.163 · Mmrm weighted z-statistic: -1.40
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.851 · Mmrm weighted z-statistic: 0.19
SecondaryStage 1 and Stage 2: Change From Baseline in the NPI Aberrant Motor Behavior Domain Score to Week 6 and Week 12

The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate aberrant motor behavior. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the NPI Aberrant Motor Behavior Domain Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline5.1 ± 3.944.9 ± 3.775.1 ± 4.07———
Change from Baseline at Week 6 Stage 2 Baseline-0.9 ± 3.62-1.6 ± 3.74-0.7 ± 3.86———
Stage 2 Baseline———5.2 ± 3.794.0 ± 3.874.3 ± 4.32
Change from Baseline at Week 12———-0.4 ± 2.160.6 ± 3.241.1 ± 3.54
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · MMRM · p = =0.146 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -0.6 · 95% CI -1.4 to 0.2
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · MMRM · p = =0.399 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: 0.3 · 95% CI -0.4 to 1.1
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · MMRM · p = =0.283 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: 0.7 · 95% CI -0.6 to 2.0
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · MMRM · p = =0.065 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: 1.2 · 95% CI -0.1 to 2.5
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.829 · Mmrm weighted z-statistic: -0.22
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.052 · Mmrm weighted z-statistic: 1.94
SecondaryStage 1 and Stage 2: Change From Baseline in the Zarit Burden Interview (ZBI) Score to Week 6 and Week 12

The ZBI is a 22-item scale used to assess the impact of a participant with dementia and also other illnesses on the caregiver's burden. For each item of the scale, the caregiver indicates how often they feel the burden (never, rarely, sometimes, quite frequently, or nearly always). The score ranges from 0 to 88 and is determined by adding the numbered responses of the individual items. Higher scores indicate greater caregiver distress. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the Zarit Burden Interview (ZBI) Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline30.9 ± 16.1930.0 ± 16.9633.0 ± 16.68———
Change from Baseline at Week 6-1.4 ± 8.22-2.0 ± 8.44-2.7 ± 9.49———
Stage 2 Baseline———31.5 ± 15.2432.0 ± 16.5728.6 ± 16.76
Change from Baseline at Week 12———-1.1 ± 7.651.4 ± 8.71-0.5 ± 7.05
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · ANCOVA · p = =0.530 · Least squares mean difference: -0.7 · 95% CI -2.7 to 1.4
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · ANCOVA · p = =0.326 · Least squares mean difference: -1.0 · 95% CI -3.1 to 1.0
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.135 · Least squares mean difference: 2.5 · 95% CI -0.8 to 5.9
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.895 · Least squares mean difference: 0.2 · 95% CI -3.1 to 3.5
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.502 · Spcd ols weighted z-statistic: 0.67
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.564 · Spcd ols weighted z-statistic: -0.58
SecondaryStage 1 and Stage 2: Change From Baseline in the NPI Irritability/Lability Domain Score to Week 6 and Week 12

The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains, including the irritability/lability domain score. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the NPI Irritability/Lability Domain Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline5.1 ± 3.335.1 ± 3.625.2 ± 3.39———
Change from Baseline at Week 6-1.1 ± 3.84-1.9 ± 3.71-1.4 ± 3.62———
Stage 2 Baseline———4.5 ± 3.995.3 ± 3.545.2 ± 3.64
Change from Baseline at Week 12———0.2 ± 3.19-1.3 ± 3.88-0.9 ± 3.45
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · MMRM · p = =0.061 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -0.8 · 95% CI -1.6 to 0.0
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · MMRM · p = =0.400 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -0.3 · 95% CI -1.1 to 0.5
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · MMRM · p = =0.115 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -1.1 · 95% CI -2.4 to 0.3
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · MMRM · p = =0.264 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -0.8 · 95% CI -2.1 to 0.6
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.015 · Mmrm weighted z-statistic: -2.44
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.163 · Mmrm weighted z-statistic: -1.40
SecondaryStage 1 and Stage 2: Change From Baseline in the NPI Total Score to Week 6 and Week 12

NPI evaluates both frequency and severity of 12 neuropsychiatric disturbances including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, as well as appetite/eating. Total domain score= frequency x severity and thus ranges from 1 to 12. NPI domain is rated by caregiver for symptom frequency and severity. Frequency is rated as: 1=occasionally, 2=often, 3= frequently, and 4=very frequently. Severity is rated as: 1=mild; 2= moderate, and 3=severe. Frequency and severity rating scales has defined anchor points to enhance reliability of caregiver responses. Caregiver distress is rated for each positive neuropsychiatric symptom using following anchored scores. It is rated as 0=not at all, 1=minimal, 3=moderate, 4=severe, 5=very severe. Total score is calculated by adding the individual Item scores, to yield a possible total scores of 0 to 144.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the NPI Total Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline40.2 ± 17.9539.4 ± 18.9340.1 ± 19.98———
Change from Baseline at Week 6-9.2 ± 17.41-13.2 ± 17.99-10.6 ± 16.09———
Stage 2 Baseline———39.2 ± 22.4734.7 ± 14.1634.6 ± 16.93
Change from Baseline at Week 12———-5.1 ± 14.03-4.4 ± 12.92-0.1 ± 18.82
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · MMRM · p = =0.050 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -3.9 · 95% CI -7.8 to -0.0
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · MMRM · p = =0.412 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -1.6 · 95% CI -5.4 to 2.2
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · MMRM · p = =0.775 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: -1.0 · 95% CI -7.8 to 5.8
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · MMRM · p = =0.333 (MMRMs include fixed effects of treatment, visit, treatment-by-visit, BL, BL-by-visit, and in the Stage 1 model, BL NPI AA, risk assessment for falls, BL concomitant antipsychotic medication use. Unstructured variance-covariance was used.) · Least squares mean difference: 3.3 · 95% CI -3.5 to 10.1
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.133 · Mmrm weighted z-statistic: -1.50
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.829 · Mmrm weighted z-statistic: 0.22
SecondaryStage 1 and Stage 2: Change From Baseline in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score to Week 6 and Week 12

The CGIS-Agitation is an observer-rated scale that measures illness severity. CGIS is used to assess the severity of agitation. The CGIS score is rated on a 7-point scale (1 = normal, not at all ill; 7 = among the most extremely ill participants). Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline4.5 ± 0.644.3 ± 0.494.4 ± 0.70———
Change from Baseline at Week 6-0.5 ± 0.78-0.7 ± 0.97-0.7 ± 1.04———
Stage 2 Baseline———4.4 ± 0.874.2 ± 0.774.1 ± 0.77
Change from Baseline at Week 12———-0.2 ± 0.58-0.4 ± 0.70-0.3 ± 1.01
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · ANCOVA · p = =0.118 · Least squares mean difference: -0.2 · 95% CI -0.4 to 0.0
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · ANCOVA · p = =0.191 · Least squares mean difference: -0.1 · 95% CI -0.4 to 0.1
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.225 · Least squares mean difference: -0.2 · 95% CI -0.5 to 0.1
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.227 · Least squares mean difference: -0.2 · 95% CI -0.5 to 0.1
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.049 · Spcd ols weighted z-statistic: -1.97
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.075 · Spcd ols weighted z-statistic: -1.78
SecondaryStage 1 and Stage 2: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Rating at Week 6 and Week 12

The ADCS-CGIC rating scale provides a reliable means to assess change from a Baseline level of global function within the time frame of the trial. ADCS-CGIC-Overall focuses on the clinician's observations of change in the participant's cognitive, functional, and behavioral performance. The ADCS-CGIC-Overall responses (1-7) are rated as: 1 = marked improvement, 2 = moderate improvement, 3 = minimal improvement, 4 = no change, 5 = minimal worsening, 6 = moderate worsening, or 7 = marked worsening. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Least squares mean · units on a scale
Stage 1 and Stage 2: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Rating at Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Week 63.7 ± 0.113.5 ± 0.143.6 ± 0.13———
Stage 2 Week 12———4.0 ± 0.173.6 ± 0.173.7 ± 0.16
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · ANCOVA · p = =0.364 · Least squares mean difference: -0.1 · 95% CI -0.4 to 0.1
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · ANCOVA · p = =0.427 · Least squares mean difference: -0.1 · 95% CI -0.4 to 0.2
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.098 · Least squares mean difference: -0.4 · 95% CI -0.9 to 0.1
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.168 · Least squares mean difference: -0.3 · 95% CI -0.8 to 0.1
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.063 · Spcd ols weighted z-statistic: -1.86
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.115 · Spcd ols weighted z-statistic: -1.57
SecondaryStage 1 and Stage 2: Patient Global Impression of Change (PGIC) Score at Week 6 and Week 12

The PGIC is a 7-point (1-7) scale used to assess treatment response: 1 = very much improved, = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Least squares mean · units on a scale
Stage 1 and Stage 2: Patient Global Impression of Change (PGIC) Score at Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Week 63.4 ± 0.123.0 ± 0.153.1 ± 0.14———
Stage 2 Week 12———3.6 ± 0.203.1 ± 0.203.3 ± 0.19
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · ANCOVA · p = =0.014 · Least squares mean difference: -0.4 · 95% CI -0.6 to -0.1
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · ANCOVA · p = =0.111 · Least squares mean difference: -0.2 · 95% CI -0.5 to 0.1
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.062 · Least squares mean difference: -0.5 · 95% CI -1.1 to 0.0
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.305 · Least squares mean difference: -0.3 · 95% CI -0.8 to 0.3
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.003 · Spcd ols weighted z-statistic: -3.01
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.073 · Spcd ols weighted z-statistic: -1.79
SecondaryStage 1 and Stage 2: Change From Baseline in the Dementia Quality of Life (DEMQOL) Score to Week 6 and Week 12

The DEMQOL scale is used to evaluate health-related QOL in participants with dementia and their caregivers. There are 2 versions of the DEMQOL: a 28-item version (rated by the participant); and a 31-item version (DEMQOL-proxy, rated by the caregiver). Both versions are recommended for evaluating participants (and their caregivers) with mild to moderate dementia. The DEMQOL total score ranges from 28 to 112. The DEMQOL-proxy is used for participants with severe dementia; the total score ranges from 31 to 124. For both versions, higher scores indicate greater QOL. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 vs \> 6), risk assessments for falls (normal/mild vs moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the Dementia Quality of Life (DEMQOL) Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline85.7 ± 10.6382.9 ± 10.2284.0 ± 11.98———
Change from Baseline at Week 62.3 ± 8.263.5 ± 8.574.4 ± 10.79———
Stage 2 Baseline———86.8 ± 9.9690.0 ± 9.5187.8 ± 10.72
Change from Baseline at Week 12———2.5 ± 5.403.1 ± 9.521.1 ± 13.06
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · ANCOVA · p = =0.909 · Least squares mean difference: 0.1 · 95% CI -2.2 to 2.5
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · ANCOVA · p = =0.226 · Least squares mean difference: 1.4 · 95% CI -0.9 to 3.8
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.405 · Least squares mean difference: 2.1 · 95% CI -2.9 to 7.1
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.714 · Least squares mean difference: -0.9 · 95% CI -5.8 to 4.0
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.456 · Spcd ols weighted z-statistic: 0.75
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.678 · Spcd ols weighted z-statistic: 0.42
SecondaryStage 1 and Stage 2: Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score to Week 6 and Week 12

The CSDD scale is used to assess signs/symptoms of major depression in participants with dementia. CSDD has 19 items, and each item is rated for severity on the following scale of 0 to 2 (0 =absent, 1= mild/intermittent 2=severe). CSDD score is calculated by summing non-missing scores from each item score. The scale ranges from 0-no depression to 38 maximum depressions. Scores above 10 indicate a probable major depression, above 18 indicate a definite major depression, and below 6 as a rule are associated with the absence of significant depressive symptoms. Higher score indicated maximum depression.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline6.2 ± 2.246.3 ± 2.116.4 ± 2.19———
Change from Baseline at Week 6-0.3 ± 3.01-0.7 ± 3.09-0.5 ± 2.93———
Stage 2 Baseline———6.6 ± 3.895.9 ± 2.786.8 ± 2.84
Change from Baseline at Week 12———-0.4 ± 2.56-0.5 ± 2.36-0.3 ± 3.09
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · ANCOVA · p = =0.278 · Least squares mean difference: -0.4 · 95% CI -1.1 to 0.3
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · ANCOVA · p = =0.817 · Least squares mean difference: -0.1 · 95% CI -0.8 to 0.6
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.500 · Least squares mean difference: -0.4 · 95% CI -1.4 to 0.7
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.795 · Least squares mean difference: 0.1 · 95% CI -0.9 to 1.2
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.213 · Spcd ols weighted z-statistic: -1.25
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.985 · Spcd ols weighted z-statistic: 0.02
SecondaryStage 2: Percentage of Participants With General Medical Health Rating (GMHR) Score

The GMHR is a global clinical rating for medical health, designed to quantify in a single number (1 to 4) the severity of general comorbidity in a participant with dementia. The ratings are: 1 = poor; 2 = fair; 3 = good; 4 = excellent to very good. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

Time frame:
Baseline; Week 12
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants With General Medical Health Rating (GMHR) Score
percentage of participantsStage 1: Placebo to Stage 2: PlaceboStage 1: Placebo to: Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mgStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg to Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Excellent to very good22.620.313.820.220.6
Good59.764.158.558.562.9
Fair11.37.816.913.811.3
Poor00000
Missing6.57.810.87.45.2
SecondaryStage 1 and Stage 2: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score to Week 6 and Week 12

The ADAS is designed to evaluate the cognitive and non-cognitive behavioral dysfunction characteristics of participants with AD. The cognitive subscale (ADAS-cog) consists of 11 subsets related to memory, praxis, and language. ADAS-cog scores range from 0 to 70. Higher scores indicate greater cognitive impairment. The ADAS-cog is assessed for participants with an Mini-Mental State Examination (MMSE) score of ≥10 at the Baseline Visit. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.

Time frame:
Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Reported as:
Mean · units on a scale
Stage 1 and Stage 2: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score to Week 6 and Week 12
units on a scaleStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mgStage 1: Placebo Non-responders to Stage 2: PlaceboStage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Stage 1 Baseline25.8 ± 10.1026.2 ± 8.9925.3 ± 8.88———
Change from Baseline at Week 6-0.5 ± 4.46-2.0 ± 4.28-0.5 ± 4.72———
Stage 2 Baseline———26.9 ± 9.5627.0 ± 9.2725.3 ± 10.91
Change from Baseline at Week 12———-0.8 ± 5.050.3 ± 4.950.1 ± 5.47
Statistical analysis
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg · ANCOVA · p = =0.018 · Least squares mean difference: -1.6 · 95% CI -2.9 to -0.3
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg · ANCOVA · p = =0.956 · Least squares mean difference: 0.0 · 95% CI -1.3 to 1.3
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.451 · Least squares mean difference: 1.1 · 95% CI -1.8 to 4.0
  • Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.519 · Least squares mean difference: 0.9 · 95% CI -1.9 to 3.7
  • Stage 1: Placebo vs Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) · ANCOVA · p = =0.471 · Spcd ols weighted z-statistic: -0.72
  • Stage 1: Placebo vs Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg vs Stage 1: Placebo Non-responders to Stage 2: Placebo vs Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) · ANCOVA · p = =0.618 · Spcd ols weighted z-statistic: 0.50
SecondaryStage 1: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals

RUD evaluates dementia participants utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. The RUD is administered as a semi-structured interview with the participant's primary caregiver and contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by caregiver) and the other focusing on the participant's use of healthcare resources. Information of caregivers who reported their responsibilities affected their work and who visited healthcare professionals from the interviews during Stage 1 is reported for this outcome measure. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

Time frame:
Stage 1: Week 6
Reported as:
Number · percentage of participants
Stage 1: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals
percentage of participantsStage 1: PlaceboStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Caregivers Who Reported that their Responsibilities Affected Their Work33.822.934.2
Caregivers Who Visited Health Care Professionals42.231.144.8
SecondaryStage 2: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals

RUD evaluates dementia participants utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. The RUD is administered as a semi-structured interview with the participant's primary caregiver and contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by caregiver) and the other focusing on the participant's use of healthcare resources. Information of caregivers who reported their responsibilities affected their work and who visited healthcare professionals from the interviews during Stage 2 is reported for this outcome measure. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

Time frame:
Stage 2: Week 12
Reported as:
Number · percentage of participants
Stage 2: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals
percentage of participantsStage 2: Placebo/PlaceboStage 1: Placebo to: Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mgStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Caregivers Who Reported that their Responsibilities Affected Their Work44.028.636.424.235.3
Caregivers Who Visited Health Care Professionals43.130.529.326.737.0
SecondaryStage 1: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant

RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on hours per day caregiver spent assisting participant from interviews during Stage 1 is reported for this outcome measure, where the following questions (Q), Q1= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as toilet visits, eating, dressing, grooming, walking, bathing? Q2= On typical care day during the last 30 days, how much time per day did you assist participant with tasks as (shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= On typical care day during last 30 days, how much time per day did you spend supervising (preventing dangerous events)?(Q3). Data is collected for treatment arm groups as pre-specified in protocol for this outcome measure.

Time frame:
Stage 1: Week 6
Reported as:
Median · hours
Stage 1: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant
hoursStage 1: PlaceboStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Week 6 (Q1)2.0 (0 to 20)2.0 (0 to 24)2.0 (0 to 15)
Week 6 (Q2)4.0 (1 to 24)4.0 (0 to 18)4.0 (1 to 15)
Week 6 (Q3)3.0 (0 to 24)2.0 (0 to 24)2.8 (0 to 24)
SecondaryStage 2: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant

RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on hours per day caregiver spent assisting participant from interviews during Stage 1 is reported for this outcome measure, where the following questions (Q), Q1= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as toilet visits, eating, dressing, grooming, walking, bathing? Q2= On typical care day during the last 30 days, how much time per day did you assist participant with tasks as (shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= On typical care day during last 30 days, how much time per day did you spend supervising (preventing dangerous events)?(Q3). Data is collected for treatment arm groups as pre-specified in protocol for this outcome measure.

Time frame:
Stage 2: Week 12
Reported as:
Median · hours
Stage 2: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant
hoursStage 1: Placebo to Stage 2: PlaceboStage 1: Placebo to Stage 2: AVP-786 18 mgStage 1: Placebo to Stage 2: AVP-786 28 mgStage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)
Week 12 (Q1)1.5 (0 to 15)2.0 (0 to 7)2.0 (0 to 12)2.0 (0 to 10)2.0 (0 to 14)
Week 12 (Q2)4.0 (0 to 16)4.0 (0 to 24)4.0 (0 to 24)4.0 (0 to 17)4.0 (0 to 15)
Week 12 (Q3)1.0 (0 to 19)3.0 (0 to 24)3.0 (0 to 20)2.0 (0 to 24)2.0 (0 to 18)
SecondaryStage 1: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant

RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on days caregiver spent assisting participant from interviews during Stage 1 is reported for outcome measure, where following questions (Q), Q1= During last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking, bathing) services to participant?; Q2= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= During last 30 days, how many days did you spend providing these services (supervising) to the participant?. Data is collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

Time frame:
Stage 1: Week 6
Reported as:
Median · days
Stage 1: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant
daysStage 1: PlaceboStage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mgStage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg
Week 6 (Q1)30.0 (0 to 30)30.0 (0 to 30)30.0 (0 to 30)
Week 6 (Q2)30.0 (0 to 30)30.0 (0 to 39)30.0 (4 to 30)
Week 6 (Q3)30.0 (0 to 30)30.0 (0 to 30)30.0 (0 to 30)
Secondary12-Week Parallel Group: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant

RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on days caregiver spent assisting participant from interviews during Stage 1 is reported for outcome measure, where following questions (Q), Q1= During last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking, bathing) services to participant?; Q2= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= During last 30 days, how many days did you spend providing these services (supervising) to the participant?. Data is collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.

Time frame:
12-Week Parallel Group: Week 12
Reported as:
Median · days
12-Week Parallel Group: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant
daysStage 1: Placebo to Stage 2: PlaceboStage 1: Placebo to Stage 2: AVP-786 18 mgStage 1: Placebo to Stage 2: AVP-786 28 mg
Week 12 (Q1)30.0 (0 to 30)30.0 (0 to 30)30.0 (0 to 30)
Week 12 (Q2)30.0 (0 to 30)30.0 (0 to 30)30.0 (0 to 30)
Week 12 (Q3)30.0 (0 to 30)30.0 (0 to 30)30.0 (0 to 30)

Adverse events

Collected over Start of treatment up to Week 16 (End of treatment plus 30 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/194 (0.5%)6/194 (3.1%)84/194 (43.3%)
AVP-786-183/156 (1.9%)17/156 (10.9%)78/156 (50%)
AVP-786-281/159 (0.6%)7/159 (4.4%)71/159 (44.7%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPlaceboAVP-786-18AVP-786-28
Urinary tract infectionInfections and infestations2/1942/1561/159
Alcohol poisoningInjury, poisoning and procedural complications0/1942/1560/159
Cerebrovascular accidentNervous system disorders0/1942/1560/159
Atrial fibrillationCardiac disorders2/1940/1560/159
Abdominal painGastrointestinal disorders0/1941/1560/159
Non-cardiac chest painGeneral disorders0/1941/1560/159
EpididymitisInfections and infestations0/1941/1560/159
SepsisInfections and infestations0/1941/1560/159
FallInjury, poisoning and procedural complications0/1941/1561/159
Femoral neck fractureInjury, poisoning and procedural complications0/1941/1560/159
Most frequent other events
Showing 10 of 186
Most frequent other events
EventPlaceboAVP-786-18AVP-786-28
FallInjury, poisoning and procedural complications12/19414/15612/159
DiarrhoeaGastrointestinal disorders5/19410/1567/159
HeadacheNervous system disorders3/19410/1562/159
Urinary tract infectionInfections and infestations9/1949/1565/159
AgitationPsychiatric disorders10/1944/1567/159
SomnolenceNervous system disorders7/1946/1564/159
ContusionInjury, poisoning and procedural complications4/1945/1562/159
DizzinessNervous system disorders5/1945/1565/159
Sinus bradycardiaCardiac disorders1/1944/1562/159
NauseaGastrointestinal disorders4/1944/1560/159

Baseline characteristics

Baseline data were collected in members of the Stage 1 Modified Intent-to-Treat (mITT) Population, comprised of all participants randomized in the study who had at least one post-Baseline efficacy assessment.

Age, Continuous
Age, Continuous(years)PlaceboAVP-786-18AVP-786-28Total
Mean76.6 ± 7.9273.8 ± 8.3974.6 ± 7.6975.4 ± 8.06
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAVP-786-18AVP-786-28Total
Female1124754213
Male794743169
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAVP-786-18AVP-786-28Total
American Indian or Alaska Native0011
Asian3115
Native Hawaiian or Other Pacific Islander0000
Black or African American126624
White1758789351
More than one race0000
Unknown or Not Reported1001
09

Study locations

126 sites
  • Clinical Research Site
    Phoenix, Arizona 85032, United States
  • Clinical Research Site
    Scottsdale, Arizona 85254, United States
  • Clinical Research Site
    Little Rock, Arkansas 72209, United States
  • Clinical Research Site#1
    Irvine, California 92697, United States
  • Clinical Research Site#2
    Irvine, California 92697, United States
  • Clinical Research Site
    Long Beach, California 90806, United States
  • Clinical Research Site
    Oceanside, California 92056, United States
  • Clinical Research Site
    Orange, California 92868, United States
  • Clinical Research Site#1
    San Diego, California 92103, United States
  • Clinical Research Site#2
    San Diego, California 92103, United States
  • Clinical Research Site
    Santa Ana, California 92704, United States
  • Clinical Research Site
    Tustin, California 92780, United States
  • Clinical Research Site
    Denver, Colorado 80209, United States
  • Clinical Research Site
    Cromwell, Connecticut 06416, United States
  • Clinical Research Site
    New London, Connecticut 06320, United States
  • Clinical Research Site
    Norwalk, Connecticut 06851, United States
  • Clinical Research Site
    Atlantis, Florida 33462, United States
  • Clinical Research Site
    Boca Raton, Florida 33428, United States
  • Clinical Research Site
    Brandon, Florida 33511, United States
  • Clinical Research Site#1
    Coral Gables, Florida 33134, United States
  • Clinical Research Site#2
    Coral Gables, Florida 33134, United States
  • Clinical Research Site#3
    Coral Gables, Florida 33134, United States
  • Clinical Research Site#1
    Deerfield Beach, Florida 33064, United States
  • Clinical Research Site
    Doral, Florida 33166, United States
  • Clinical Research Site
    Hialeah, Florida 33012, United States
  • Clinical Research Site#1
    Hialeah, Florida 33016, United States
  • Clinical Research Site#2
    Hialeah, Florida 33016, United States
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
  • Clinical Research Site
    Kendall, Florida 33175, United States
  • Clinical Research Site
    Kissimmee, Florida 34741, United States
  • Clinical Research Site
    Kissimmee, Florida 34744, United States
  • Clinical Research Site
    Lake Worth, Florida 33449, United States
  • Clinical Research Site
    Miami, Florida 33122, United States
  • Clinical Research Site#1
    Miami, Florida 33125, United States
  • Clinical Research Site#2
    Miami, Florida 33125, United States
  • Clinical Research Site
    Miami, Florida 33126, United States
  • Clinical Research Site
    Miami, Florida 33133, United States
  • Clinical Research Site#1
    Miami, Florida 33135, United States
  • Clinical Research Site#2
    Miami, Florida 33135, United States
  • Clinical Research Site
    Miami, Florida 33136, United States
  • Clinical Research Site
    Miami, Florida 33137, United States
  • Clinical Research Site
    Miami, Florida 33144, United States
  • Clinical Research Site
    Miami, Florida 33145, United States
  • Clinical Research Site
    Miami, Florida 33165, United States
  • Clinical Research Site
    Miami, Florida 33175, United States
  • Clinical Research Site#2
    Miami, Florida 33176, United States
  • Clinical Research Site
    Miami, Florida 33183, United States
  • Clinical Research Site
    Miami, Florida 33467, United States
  • Clinical Research Site
    Naples, Florida 34102, United States
  • Clinical Research Site
    Oakland Park, Florida 33334, United States
  • Clinical Research Site
    Orlando, Florida 32819, United States
  • Clinical Research Site
    Ormond Beach, Florida 32174, United States
  • Clinical Research Site
    Palm Beach Gardens, Florida 33410, United States
  • Clinical Research Site
    Palmetto Bay, Florida 33157, United States
  • Clinical Research Site#2
    Pompano Beach, Florida 33064, United States
  • Clinical Research Site
    Saint Petersburg, Florida 33713, United States
  • Clinical Research Site
    Sarasota, Florida 34243, United States
  • Clinical Research Site#1
    Tampa, Florida 33609, United States
  • Clinical Research Site#2
    Tampa, Florida 33609, United States
  • Clinical Research Site#2
    Tampa, Florida 33613, United States
  • Clinical Research Site
    Tampa, Florida 33634, United States
  • Clinical Research Site
    The Villages, Florida 32162, United States
  • Clinical Research Site
    West Palm Beach, Florida 33407, United States
  • Clinical Research Site
    Winter Park, Florida 32789, United States
  • Clinical Research Site
    Atlanta, Georgia 30342, United States
  • Clinical Research Site
    Newnan, Georgia 30265, United States
  • Clinical Research Site
    Honolulu, Hawaii 96817, United States
  • Clinical Research Site
    Schaumburg, Illinois 60194, United States
  • Clinical Research Site
    Indianapolis, Indiana 46202, United States
  • Clinical Research Site
    Lenexa, Kansas 66214, United States
  • Clinical Research Site
    Paducah, Kentucky 42003, United States
  • Clinical Research Site
    Bedford, Massachusetts 01730, United States
  • Clinical Research Site
    Quincy, Massachusetts 02169, United States
  • Clinical Research Site
    Ann Arbor, Michigan 48105, United States
  • Clinical Research Site
    Paw Paw, Michigan 49079, United States
  • Clinical Research Site
    Hattiesburg, Mississippi 39401, United States
  • Clinical Research Site
    Creve Coeur, Missouri 63141, United States
  • Clinical Research Site
    Saint Louis, Missouri 63128, United States
  • Clinical Research Site
    Mount Arlington, New Jersey 07856, United States
  • Clinical Research Site
    Toms River, New Jersey 08755, United States
  • Clinical Research Site
    West Long Branch, New Jersey 07764, United States
  • Clinical Research Site
    Amherst, New York 14226, United States
  • Clinical Research Site
    Brooklyn, New York 11229, United States
  • Clinical Research Site
    New York, New York 10032, United States
  • Clinical Research Site
    New York, New York 10036, United States
  • Clinical Research Site
    Orangeburg, New York 10962, United States
  • Clinical Research Site
    Rochester, New York 14620, United States
  • Clinical Research Site
    Staten Island, New York 10312, United States
  • Clinical Research Site
    Durham, North Carolina 27710, United States
  • Clinical Research Site
    Winston-Salem, North Carolina 27157, United States
  • Clinical Research Site
    Akron, Ohio 44320, United States
  • Clinical Research Site
    Cincinnati, Ohio 45219, United States
  • Clinical Research Site#1
    Columbus, Ohio 43210, United States
  • Clinical Research Site#2
    Columbus, Ohio 43210, United States
  • Clinical Research Site
    Dayton, Ohio 45459, United States
  • Clinical Research Site
    Westerville, Ohio 43082, United States
  • Clinical Research Site
    Edmond, Oklahoma 73012, United States
  • Clinical Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Clinical Research Site
    Oklahoma City, Oklahoma 73106, United States
  • Clinical Research Site
    Oklahoma City, Oklahoma 73112, United States

Showing the first 100 of 126 sites across 6 countries. Choose a country and city above to see the rest.

10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jan 2019, 42 months.

Results were first posted in Feb 2023, 4 years after primary completion. A results delay was requested in Jan 2020.

Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2015
First posted
May 13, 2015
StartActual
Jul 23, 2015
Primary completionActual
Jan 30, 2019
CompletionActual
Feb 27, 2019
Results delay requested
Jan 29, 2020
Results first posted
Feb 13, 2023
Last update
Feb 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02442765
Responsible party
Sponsor
First posted
May 13, 2015
Start date
Jul 23, 2015
Primary completion
Jan 30, 2019
Completion
Feb 27, 2019
Results posted
Feb 13, 2023
Last update
Feb 13, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deudextromethorphan · Quinidine

Start the discussion